Biolase (BIOL) Prices $6.9 Million Registered Direct Offering of Common Stock, Warrants

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately $6.9 million of its common stock in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common stock in a concurrent private placement. The combined purchase price for one share of common stock and warrant to purchase one share of common stock will be $0.64.

Under the terms of the securities purchase agreement, BIOLASE has agreed to sell 10,800,000 shares of common stock. In a private placement, which will be consummated concurrently with the Offering, BIOLASE also has agreed to issue warrants to purchase up to an aggregate of 10,800,000 shares of common stock. The warrants will be immediately exercisable, will expire 5.5 years from the date of issuance and will have an exercise price of $0.515 per common share.

The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $6.9 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about June 10, 2020, subject to the satisfaction of customary closing conditions.

Maxim Group LLC, The Benchmark Company, LLC & Colliers Securities LLC are acting as co-placement agents for the offering.

The shares of common stock are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-233172) previously filed and declared effective by the Securities and Exchange Commission (SEC).

You May Also Be Interested In

• ClearSign Technologies (CLIR) Prices $9.3M Share and Warrant Offering at $0.91/sh
• Progress Software Corporation (PRGS) Issues Statement on a Possible Offer for MariaDB
• Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh